Seven Bridges, a bioinformatics provider, is supporting Pfizer in the development of a data management and collaboration solution for Pfizer’s single-cell ribonucleic acid (RNA) sequencing (scRNASeq) data. The cloud-based Seven Bridges Platform is for conducting bioinformatic analyses in which research teams can store, analyze and interpret their data. The partnership aims to expand Pfizer’s cloud platforms and capabilities, a key component of its digital cloud and advanced analytics.
 
Sequencing RNA provides fundamental insights into the regulation of genomes. scRNASeq yields potentially useful information, but the scRNASeq data carry a very large data footprint.
 
Seven Bridges will centralize and manage terabytes of raw and processed scRNASeq data, which provides detailed analysis of gene expression in individual cells.
 
“Interpreting large-scale, complex transcriptomics data is critically important for understanding the molecular and cellular basis of disease,” said Enoch Huang, Vice President, Medicinal Sciences, Pfizer. “We are confident that by working with the unique multi-cloud technology developed by Seven Bridges and by benefiting from the depth and breadth of their expertise in bioinformatics and cloud computing, their solution will assist us in maximizing the value of the data we generate.”
 
“Seven Bridges believes that genomics—and single-cell RNA sequencing in particular—will continue to play an increasingly vital role in the discovery of novel drugs and vaccines,” said Bill Moss, CEO, Seven Bridges. “We are thrilled that Pfizer has chosen our platform to help the company address these unique data management needs. And we look forward to supporting the development of a scRNASeq data storage solution that meets Pfizer’s research and development requirements.”